200 Participants Needed

Serplulimab + Chemotherapy for Small Cell Lung Cancer

Recruiting at 121 trial locations
MV
JW
JL
NJ
IS
EM
RH
WA
Overseen ByWallace Akerley
Age: 18+
Sex: Any
Travel: May Be Covered
Trial Phase: Phase 3
Sponsor: Shanghai Henlius Biotech
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you are using denosumab for bone metastases, you must switch to bisphosphonate therapy before and during the trial.

What data supports the effectiveness of the drug combination Serplulimab plus chemotherapy for small cell lung cancer?

The ASTRUM-005 trial showed that adding Serplulimab to chemotherapy improved survival in patients with extensive-stage small cell lung cancer compared to chemotherapy alone.12345

Is the combination of Serplulimab and chemotherapy generally safe for humans?

Serplulimab combined with chemotherapy has been shown to have a manageable safety profile in clinical trials for various cancers, including lung and esophageal cancers. While it can cause serious side effects in some patients, the overall safety is considered acceptable compared to chemotherapy alone.13678

How is the drug Serplulimab plus chemotherapy different for treating small cell lung cancer?

Serplulimab is an anti-PD-1 antibody that helps the immune system fight cancer by reducing immunosuppression, and when combined with chemotherapy, it has shown survival benefits for patients with extensive-stage small-cell lung cancer compared to chemotherapy alone. This combination is particularly novel as there is no standard treatment for transformed small cell lung cancer, making it a promising option for patients with this aggressive disease.123910

Eligibility Criteria

This trial is for US patients newly diagnosed with extensive-stage small cell lung cancer (ES-SCLC) who are fully mobile and have not received prior treatment. Eligible participants must not have other active cancers, except certain cured skin or in situ cancers, and should test negative for HIV, Hepatitis B/C. They cannot join if they've had a solid organ or bone marrow transplant, cervical/bladder/skin cancer, peripheral neuropathy, or brain metastasis.

Inclusion Criteria

I have no active cancer and no history of cancer in the last 5 years, except for certain skin, bladder, prostate, cervical, or breast cancers that were treated and cured.
Answer yes if you do not have HIV, Hepatitis B or Hepatitis C
I do not have brain metastasis or carcinomatous meningitis.
See 3 more

Exclusion Criteria

I have been diagnosed with cervical cancer.
You have been diagnosed with HIV, Hepatitis B, or Hepatitis C.
I have been newly diagnosed with extensive-stage small cell lung cancer.
See 15 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either Serplulimab or Atezolizumab plus chemotherapy (carboplatin-etoposide)

14 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

10 months

Long-term follow-up

Participants are monitored for overall survival and progression-free survival

24 months

Treatment Details

Interventions

  • Atezolizumab
  • Carboplatin
  • Etoposide
  • HLX10
Trial OverviewThe study compares the efficacy and safety of two treatments: Serplulimab plus chemotherapy (carboplatin-etoposide) versus Atezolizumab plus the same chemotherapy in untreated ES-SCLC patients. Participants will be randomly assigned to either Arm A (Serplulimab group) or Arm B (Atezolizumab control group).
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Serplulimab + chemotherapyExperimental Treatment1 Intervention
Serplulimab + chemotherapy (carboplatin-etoposide)
Group II: Atezolizumab + chemotherapyActive Control1 Intervention
Atezolizumab + chemotherapy (carboplatin-etoposide)

HLX10 is already approved in China, European Union for the following indications:

🇨🇳
Approved in China as Hansizhuang for:
  • Microsatellite Instability-High (MSI-H) solid tumors
  • Squamous non-small cell lung cancer (sqNSCLC)
  • Extensive-stage small cell lung cancer (ES-SCLC)
  • Esophageal squamous cell carcinoma (ESCC)
🇪🇺
Approved in European Union as Hetronifly for:
  • Extensive-stage small cell lung cancer (ES-SCLC)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Shanghai Henlius Biotech

Lead Sponsor

Trials
100
Recruited
19,200+

Dr. Jason Zhu

Shanghai Henlius Biotech

Chief Executive Officer since 2023

MBA from Yale University

Dr. Jun Zhu

Shanghai Henlius Biotech

Chief Medical Officer

MD from an unspecified institution

Findings from Research

This ongoing phase II clinical trial is evaluating the combination of serplulimab with chemotherapy (etoposide and carboplatin) in 36 patients with transformed small cell lung cancer (T-SCLC) that originated from EGFR-mutant non-small cell lung cancer (NSCLC).
The primary goal of the study is to assess progression-free survival, with secondary goals including overall survival and safety, addressing the urgent need for effective treatments in this aggressive cancer type.
Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study.Huang, J., Zhang, XH., Cai, Y., et al.[2023]
The combination of serplulimab and chemotherapy (etoposide and carboplatin) significantly improves survival outcomes in patients with extensive-stage small-cell lung cancer (ES-SCLC), yielding 1.217 quality-adjusted life-years (QALYs) compared to 0.885 QALYs with chemotherapy alone.
From a cost-effectiveness perspective, the combination treatment has an incremental cost-effectiveness ratio (ICER) of $12,077 per QALY, making it a cost-effective first-line option for ES-SCLC patients in China, especially for specific subgroups like former smokers and those with brain metastases.
Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.Zhu, Y., Liu, K., Qin, Q., et al.[2023]
Serplulimab is an anti-PD-1 antibody that stimulates immune responses by counteracting PD-1-related immunosuppression, making it a promising treatment for solid tumors.
It received its first approval in China on March 25, 2022, specifically for adult patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) solid tumors that did not respond to previous treatments.
Serplulimab: First Approval.Lee, A.[2022]

References

Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study. [2023]
Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis. [2023]
Serplulimab: First Approval. [2022]
Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China. [2023]
Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study. [2023]
Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis. [2023]
The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients: An updated systematic review and meta-analysis. [2022]
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. [2023]
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing. [2023]
Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer. [2023]